Antibiotic Prophylaxis for Open Fractures
Direct Recommendation
For open fractures, initiate cefazolin immediately (within 3 hours of injury) as monotherapy for Gustilo-Anderson type I and II fractures, continuing for no more than 24 hours after wound closure; extended-spectrum coverage beyond gram-positive organisms is not recommended and does not improve outcomes. 1, 2
Timing: The Critical 3-Hour Window
Antibiotics must be started within 3 hours of injury—delays beyond this threshold significantly increase infection risk. 1, 3 This is non-negotiable and represents one of the most common pitfalls in open fracture management. 1
- For patients requiring surgery, administer antibiotics within 60 minutes before incision if they haven't already received them. 4, 1
Antibiotic Selection by Gustilo-Anderson Classification
Type I and II Fractures
Use cefazolin (first-generation cephalosporin) as monotherapy. 1, 5
- Targets Staphylococcus aureus, streptococci, and aerobic gram-negative bacilli. 4, 5
- The Surgical Infection Society explicitly recommends AGAINST extended-spectrum coverage for type I/II fractures—it does not decrease infectious complications, hospital length of stay, or mortality. 1, 2
- Routine MRSA coverage with vancomycin is not recommended unless specific institutional epidemiologic concerns exist. 1, 5
Type III Fractures
Continue cefazolin monotherapy for type III fractures without bone loss. 1, 2
- The Surgical Infection Society recommends AGAINST adding aminoglycosides or extended gram-negative coverage for type III fractures, as this does not improve outcomes. 1, 2
- This represents a significant departure from older guidelines that recommended adding aminoglycosides to all type III fractures. 4, 3
Type III Fractures WITH Bone Loss
Add local antibiotic delivery systems (antibiotic-impregnated beads, gentamicin-coated implants) in addition to systemic cefazolin. 1, 5, 2
- This is the only scenario where additional antimicrobial strategies beyond gram-positive coverage are recommended. 1, 2
Special Contamination Scenarios
For farm-related injuries or gross soil contamination, add penicillin to cover anaerobic organisms including Clostridium species. 1, 5
Duration of Therapy
Type I and II Fractures
Continue antibiotics for no more than 24 hours after wound closure. 1, 5
Type III Fractures
Continue antibiotics for 48-72 hours post-injury but no more than 24 hours after wound closure. 1, 2
- Extending antibiotics beyond these timeframes without evidence of infection increases antibiotic resistance risk without benefit. 4, 1
Critical Pitfalls to Avoid
Delaying antibiotic administration beyond 3 hours post-injury is the single most impactful error. 1, 3
Over-reliance on antibiotics without adequate surgical debridement—antibiotics are adjuncts to proper debridement, not replacements. 1, 7
Using cultures obtained immediately post-injury to guide prophylaxis—initial wound cultures do not correlate with infecting pathogens and should not direct antibiotic choice. 3
Continuing antibiotics beyond recommended duration without evidence of infection—this increases resistance without improving outcomes. 4, 1
Adding aminoglycosides or extended-spectrum coverage to type I, II, or III fractures without bone loss—current high-quality evidence shows no benefit. 1, 2
Dosing Considerations
Cefazolin 2g IV is the standard dose for adults. 7
- Adjust for pediatric patients based on weight. 7
- Re-dose every 4 hours during prolonged procedures based on the drug's half-life. 7
- Adjust for renal function as needed. 5
Alternative Regimens
For patients with true beta-lactam allergies, ciprofloxacin may be considered given its broad-spectrum coverage, bactericidal activity, and good bioavailability. 4
- However, this is based on older evidence and should be used cautiously given current fluoroquinolone safety concerns. 4
Evidence Quality Note
The 2022 Surgical Infection Society guidelines 2 represent the highest quality and most recent evidence, explicitly recommending against extended-spectrum coverage that was standard in older protocols. 4, 3, 8, 6 This paradigm shift is based on recognition that broader antibiotic coverage does not improve outcomes but does increase resistance and adverse effects. 1, 2